Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

Apr 14, 2025

SELL
$3.06 - $3.59 $966 - $1,134
-316 Reduced 71.33%
127 $443,000
Q1 2025

Apr 07, 2025

BUY
$3.06 - $3.59 $783 - $919
256 Added 136.9%
443 $127,000
Q4 2023

Feb 01, 2024

BUY
$1.69 - $2.54 $316 - $474
187 New
187 $443,000

Others Institutions Holding ABUS

About Arbutus Biopharma Corp


  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $678M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track This Portfolio

Track Gamma Investing LLC Portfolio

Follow Gamma Investing LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gamma Investing LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gamma Investing LLC with notifications on news.